|
|
Found results for
 patents
1.
|
2-INDOLYL IMIDAZO⏧4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER
| Application Number |
IB2006051675 |
| Publication Number |
2006/126177 |
| Status |
In Force |
| Filing Date |
2006-05-25 |
| Publication Date |
2006-11-30 |
| Owner |
GENESENSE TECHNOLOGIES INC. (Canada)
|
| Inventor |
- Huesca, Mario
- Young, Aiping, H.
- Lee, Yoon
- Khine, Aye Aye
- Wright, Jim, A.
- Lock, Lisa
- Al-Qawasmeh, Raed
|
Abstract
2-indolyl imidazo⏧4,5-dlphenanthroline compounds of Formula I that are capable of intracellular chelation of transition metals and of exerting antiproliferative effects in cancer cells, that are cytostatic and/or cytotoxic, are provided. Compounds of Formula I can also induce apoptosis in cancer cells and are thus capable of exerting a cytotoxic effect on cancer cells. The compounds of Formula I are also capable of selectively inhibiting the proliferation of one or more of prostate cancer cells, colon cancer cells, non-small lung cancer cells and leukemia cells. The compounds of Formula I are also capable of increasing the expression of the zinc-regulated tumour suppressor, KLF4 and thus are useful in inhibiting the proliferation of cancer cells in which KLF4 functions as a tumour-suppressor, including, but not limited to, bladder cancer, cancers of the gastrointestinal tract and various leukemias.
IPC Classes ?
- C07D 471/14 - Ortho-condensed systems
- A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
- A61P 35/00 - Antineoplastic agents
|
2.
|
USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER
| Application Number |
CA2006000311 |
| Publication Number |
2006/094384 |
| Status |
In Force |
| Filing Date |
2006-03-08 |
| Publication Date |
2006-09-14 |
| Owner |
GENESENSE TECHNOLOGIES INC. (Canada)
|
| Inventor |
- Wright, Jim, A.
- Young, Aiping, H.
- Lee, Yoon
- Cao, Ming, Yu
|
Abstract
The use of interleukin 17E to inhibit tumour growth in a subject is provided. The interleukin 17E can be provided to the subject exogenously, as an interleukin 17E polypeptide or a polynucleotide encoding an interleukin 17E polypeptide, or it can be provided by stimulating production of endogenous interleukin 17E. Also provided is the use of interleukin 17E in combination with one or more anti-cancer therapeutics for inhibiting tumour growth in a subject. Anti-cancer therapeutics include, for example, standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation and antisense therapy.
IPC Classes ?
- A61K 38/20 - Interleukins
- A61K 31/4164 - 1,3-Diazoles
- A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
- A61K 35/413 - Gall bladderBile
- A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
- A61P 35/00 - Antineoplastic agents
|
|
